Mersana Therapeutics (MRSN) & Eagle Pharmaceuticals (EGRX) Financial Review

Mersana Therapeutics (NASDAQ: MRSN) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

How to Become a New Pot Stock Millionaire

This table compares Mersana Therapeutics and Eagle Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mersana Therapeutics N/A N/A N/A
Eagle Pharmaceuticals 21.94% 34.16% 23.74%

Institutional & Insider Ownership

75.7% of Mersana Therapeutics shares are owned by institutional investors. 19.5% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Mersana Therapeutics and Eagle Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mersana Therapeutics 0 1 4 0 2.80
Eagle Pharmaceuticals 1 0 2 0 2.33

Mersana Therapeutics currently has a consensus target price of $26.00, indicating a potential upside of 73.68%. Eagle Pharmaceuticals has a consensus target price of $63.33, indicating a potential upside of 21.79%. Given Mersana Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Mersana Therapeutics is more favorable than Eagle Pharmaceuticals.

Valuation and Earnings

This table compares Mersana Therapeutics and Eagle Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mersana Therapeutics $17.55 million 19.49 -$38.70 million ($3.22) -4.65
Eagle Pharmaceuticals $236.71 million 3.26 $51.94 million $3.37 15.43

Eagle Pharmaceuticals has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eagle Pharmaceuticals beats Mersana Therapeutics on 8 of the 13 factors compared between the two stocks.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

DigitalNote Price Hits $0.0140 on Top Exchanges
DigitalNote Price Hits $0.0140 on Top Exchanges
BitCoal  Price Tops $0.0209
BitCoal Price Tops $0.0209
Reviewing NGL Energy Partners  & Macquarie Infrastructure
Reviewing NGL Energy Partners & Macquarie Infrastructure
Comparing Encore Capital Group  & CPI Card Group
Comparing Encore Capital Group & CPI Card Group
Financial Survey: Research Frontiers  and Its Rivals
Financial Survey: Research Frontiers and Its Rivals
Reviewing Skyworks Solutions  & Sigma Designs
Reviewing Skyworks Solutions & Sigma Designs


© 2006-2018 Ticker Report. Google+.